Exhibit 99


[Wyeth Logo]                                            N E W S  R E L E A S E


IMMEDIATE RELEASE

Media Contact:                              Investor Contact:
Natalie de Vane                             Justin Victoria
Wyeth                                       Wyeth
(484) 865-5139                              (973) 660-5340

Douglas Petkus
Wyeth Pharmaceuticals
(484) 865-5140


              Wyeth Confirms Support for Proposed Seventh Amendment
                        to National Diet Drug Settlement

                  Amendment Must Still Undergo Judicial Review


     Madison, N.J., January 10, 2005 - Wyeth (NYSE: WYE) today confirmed that it
would support the proposed Seventh Amendment to the National Diet Drug
Settlement, clearing the way for a fairness hearing on the Amendment scheduled
for January 18 before Judge Harvey Bartle III of the Eastern District of
Pennsylvania. Wyeth's deadline for exercising its walkaway right to the
Amendment was January 8.

     Executed in May 2004, the Seventh Amendment to the Settlement Agreement
would create a new claims processing structure, funding arrangement and payment
schedule for Matrix Level I or II claims, the least serious but most numerous
claims in the Settlement. The Court granted preliminary approval of the
Amendment on August 26, 2004, and directed that notice be provided to the class.
Class members had until November 9, 2004 to decide whether to be subject to the
Amendment or to opt out and remain bound by the terms of the original Settlement
Agreement. Class members who have pending more serious claims (Matrix Level
III-V) are not affected by the Seventh Amendment and would remain eligible to
have those claims processed under the existing Settlement Agreement and receive
the current Matrix amounts, if those claims are found to be valid. The
Settlement Trust is a separate legal entity and operates completely
independently of Wyeth.

     "Although the proposed Amendment must undergo further judicial review, we
are encouraged by the greater than 95 percent level of participation by class
members in the Settlement," says Lawrence V. Stein, Senior Vice President and
General Counsel of Wyeth. "The proposed Amendment ensures that the large
majority of class members who have less serious claims will receive compensation
on a streamlined basis. And it preserves funds in the existing Trust for the
more serious claims. It also would help resolve much of the uncertainty that has
surrounded the diet drug settlement - for both class members and for Wyeth."

     If approved by the courts, the proposed Seventh Amendment would include the
following key terms:

     o    The Amendment would create a new Supplemental Fund, to be administered
          by a Fund Administrator appointed by the District Court. Following
          approval by the federal court overseeing the Settlement and any
          appellate courts, the Company would ultimately deposit a total of
          $1,275.0 million, net of certain credits, into the Supplemental Fund;



                                    Page 1



     o    All current matrix Level I and II claimants who qualify under the
          Seventh Amendment, who pass the supplemental Fund's medical review and
          who otherwise satisfy the requirements of the Settlement, would
          receive a pro rata share of the $1,275.0 million Supplemental Fund,
          after deduction of certain expenses and other amounts from the
          Supplemental Fund. The pro rata amount would vary depending upon the
          number of claimants who pass medical review, the nature of their
          claims, their age and other factors. A Seventh Amendment participant
          who does not qualify for a payment after such medical review would be
          paid $2,000 from the Supplemental Fund;

     o    The Amendment would preclude future Level I and Level II matrix
          claims. Participating class members who in the future may have become
          eligible to file Level I and Level II matrix claims would receive a
          $2,000 payment from the Settlement Trust; such payments would be
          funded by the Company apart from its other funding obligations under
          the national settlement;

     o    If the participants in the Seventh Amendment have heart valve surgery
          or certain other more serious medical conditions by December 31, 2011,
          they would remain eligible to submit claims to the existing Settlement
          Trust and be paid the current matrix amounts if they qualify for such
          payments under terms modified by the Seventh Amendment. In the event
          the existing Settlement Trust is unable to pay those claims, the
          Company would guarantee payment; and

     o    All class members who participate in the Seventh Amendment would give
          up any further opt-out rights. Approval of the Seventh Amendment would
          also preclude any lawsuits by the Trust or the Company to recover any
          amounts previously paid to class members by the Trust, as well as
          terminate the Claims Integrity Program as to all claimants who
          participate in the Seventh Amendment.

     The Company is evaluating potential additional charges relating to the diet
drug litigation in connection with the preparation of its year-end financial
statements.

     Wyeth is one of the world's largest research-driven pharmaceutical and
health care products companies. It is a leader in the discovery, development,
manufacturing, and marketing of pharmaceuticals, vaccines, biotechnology
products and nonprescription medicines that improve the quality of life for
people worldwide. The Company's major divisions include Wyeth Pharmaceuticals,
Wyeth Consumer Healthcare and Fort Dodge Animal Health.

                                     ######








                                    Page 2